Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) An isolated peptide having a modified amino acid residue, said isolated peptide having an amino acid sequence selected from the group consisting of:

$(X1)_n$EVEKIKTTVKESATEEKLTPVX2L(~~X2~~ X3)$_m$ (SEQ ID NO: 1),

wherein

n ~~represents~~ and m independently represent 0 or 1;

X1 is GVKETPQQKYQRLLHEVQELTT (SEQ ID NO: 3),

X2 is L, and

X3 is AKQLAAL (SEQ ID NO: 22), or

a fragment thereof or a derivative thereof having at least about ~~90%~~ 95% identity with SEQ ID NO: 1, wherein said modified amino acid residue is selected from a protected amino terminal amino acid, a protected carboxy terminal amino acid, and an amino acid having an added fatty-acid or an polyisoprenoid side chain, and said peptide is capable of modulating cellular proliferation.

2. (currently amended) The isolated peptide of claim 1 which ~~is~~ has the amino acid sequence

GVKETPQQKYQRLLHEVQELTTEVEKIKTTVKESATEEKLTPVX2LAKQLAAL (SEQ ID NO: 51),

wherein X2 is as defined in claim 1.

3-9. (canceled)

10. (original) The peptide of claim 1 capable of inhibiting cellular proliferation.

11. (currently amended) The peptide of claim 10 capable of ~~selective~~ inhibition of proliferation of cancerous cells.

12-14. (canceled)

15. (currently amended) A composition comprising a peptide consisting of the peptide of claim 1 in admixture with a pharmaceutically acceptable carrier.

16. (canceled)

17. (currently amended) A method for inhibiting cellular proliferation comprising delivering to a target cell an effective amount of an isolated peptide consisting of the peptide of claim 1 or a nucleic acid encoding the amino acid sequence of said peptide.

18-20. (canceled)

21. (original) The method of claim 17 wherein said target cell is a tumor cell.

22. (original) The method of claim 21 wherein said tumor cell is a cancer cell.

23-27. (canceled)